Mass Medical Angels
David Fogel, CPA, is a seasoned finance professional with extensive experience as the Managing Director and Founder of Swifton CFOs LLC, providing outsourced CFO services to emerging businesses across diverse industries, including biotech and consumer marketing. Fogel has served as an adjunct faculty member at Northeastern University, teaching entrepreneurial finance in MBA and undergraduate programs, and holds significant roles as an investor and member of screening and due diligence committees for Mass Medical Angels and Beacon Angels. Fogel is also actively involved with the Cleantech Open as a Lead Generalist Mentor, a member of the Angel Capital Association, and holds positions as Chief Financial Officer and seed investor for Navigation Sciences, SAGA Diagnostics, and Chromatan Corporation. Fogel's community contributions include serving as Treasurer and a board member for the Cambridge Art Association. Educational credentials include a BS in Business with concentrations in Marketing, Finance, and Accounting from Miami University, and an MBA in Finance from the University of Cincinnati.
This person is not in any teams
Mass Medical Angels
Mass Medical Angels (MA2) was founded to answer the need for a dedicated life-science centric angel group in New England. The Boston area is a world-leading supercluster for medical innovation, but all early-stage companies in the field have tremendous difficulty with first round funding. Our goal is to provide money and mentoring to the life science community to achieve superior returns for our group, and more clinical innovation for the community. Our focus is on early stage life science companies looking to raise $250K to $3.0M. Depending on the amount of funding needed, we can fund all or a portion of the round, and will work closely with other angel groups or venture funds in the area to complete the round. We are looking for companies that are extremely capital efficient opportunities where our funds will lead to significant step-ups in valuation to avoid unfavorable future funding rounds.